Literature DB >> 24333727

MicroRNA miR-302 inhibits the tumorigenicity of endometrial cancer cells by suppression of Cyclin D1 and CDK1.

Gui-Jun Yan1, Fei Yu2, Bin Wang1, Huai-Jun Zhou3, Qiu-Yan Ge1, Jing Su1, Ya-Li Hu1, Hai-Xiang Sun4, Li-Jun Ding5.   

Abstract

MicroRNA miR-302 has been found to induce some tumor cell lines to "transdifferentiate" into miRNA-induced pluripotent stem cells (mirPS), thereby inhibiting tumor cell proliferation and reducing tumorigenicity. This study firstly found that miR-302 inhibited the proliferation and migration of endometrial cell line, Ishikawa and HEC-1-B, and arrested cell cycle at the G2/M phase. In addition, miR-302 inhibited tumorigenicity in immunodeficient mice transplanted with Ishikawa cells. Microarray and Western blotting results showed that miR-302 significantly inhibited CDK1 and Cyclin D1 gene expression in Ishikawa cells. MiR-302 directly targeted Cyclin D1, but indirectly regulated CDK1 gene expression.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  G2/M phase; HEC-1-B cells; Ishikawa cells; MicroRNA miR-302

Mesh:

Substances:

Year:  2013        PMID: 24333727     DOI: 10.1016/j.canlet.2013.11.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  24 in total

1.  Downregulation of the Genes Involved in Reprogramming (SOX2, c-MYC, miR-302, miR-145, and P21) in Gastric Adenocarcinoma.

Authors:  Mitra Khalili; Mohammad Vasei; Davood Khalili; Kamran Alimoghaddam; Majid Sadeghizadeh; Seyed Javad Mowla
Journal:  J Gastrointest Cancer       Date:  2015-09

2.  miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3.

Authors:  Yi Zhang; Wei Huang; Yan Ran; Yan Xiong; Zibiao Zhong; Xiaoli Fan; Zhenghua Wang; Qifa Ye
Journal:  Tumour Biol       Date:  2015-05-23

3.  MiR-302/367 regulate neural progenitor proliferation, differentiation timing, and survival in neurulation.

Authors:  Si-Lu Yang; Mei Yang; Stephanie Herrlinger; Chen Liang; Fan Lai; Jian-Fu Chen
Journal:  Dev Biol       Date:  2015-10-09       Impact factor: 3.582

4.  MicroRNA-302 inhibits cell migration and invasion in cervical cancer by targeting DCUN1D1.

Authors:  Yongjie Jiang; Ruijie Hou; Shaoping Li; Shaoru Li; Ge Dang
Journal:  Exp Ther Med       Date:  2018-05-25       Impact factor: 2.447

5.  Integrated microRNA and mRNA transcriptome sequencing reveals the potential roles of miRNAs in stage I endometrioid endometrial carcinoma.

Authors:  Hanzhen Xiong; Qiulian Li; Shaoyan Liu; Fang Wang; Zhongtang Xiong; Juan Chen; Hui Chen; Yuexin Yang; Xuexian Tan; Qiuping Luo; Juan Peng; Guohong Xiao; Qingping Jiang
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

6.  Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.

Authors:  Yan Zhou; Shuchen Lin; Kuo-Fu Tseng; Kun Han; Yaling Wang; Zhi-Hua Gan; Da-Liu Min; Hai-Yan Hu
Journal:  BMC Cancer       Date:  2016-10-21       Impact factor: 4.430

7.  Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo.

Authors:  Jian-Cai Tang; Jia Zhao; Feng Long; Jian-Ye Chen; Bo Mu; Zhen Jiang; Yonggan Ren; Jian Yang
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

Review 8.  MicroRNAS in endometrial cancer: recent advances and potential clinical applications.

Authors:  Megumi Yanokura; Kouji Banno; Miho Iida; Haruko Irie; Kiyoko Umene; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  EXCLI J       Date:  2015-02-02       Impact factor: 4.068

9.  Inhibition of PHLPP2/cyclin D1 protein translation contributes to the tumor suppressive effect of NFκB2 (p100).

Authors:  Jiawei Xu; Yulei Wang; Xiaohui Hua; Jiheng Xu; Zhongxian Tian; Honglei Jin; Jingxia Li; Xue-Ru Wu; Chuanshu Huang
Journal:  Oncotarget       Date:  2016-06-07

Review 10.  The miR-302/367 cluster: a comprehensive update on its evolution and functions.

Authors:  Zeqian Gao; Xueliang Zhu; Yongxi Dou
Journal:  Open Biol       Date:  2015-12       Impact factor: 6.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.